
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is projecting an increase in GAAP earnings, with expectations for $4.73 per diluted share in 2025 and $5.17 per diluted share in 2026, reflecting a positive growth trajectory bolstered by the strength in its Human Nutrition and Health segment. The company is witnessing improvements in gross and net margins, with revenue growth noted at a 9.8% increase from the previous year, driven by strong sales performance and operational efficiency. Furthermore, Balchem’s strong balance sheet positions it to potentially become debt-free by the end of the year, allowing for opportunities to pursue accretive mergers and acquisitions.
Bears say
Balchem Corporation's forecasts for earnings in 2026 have been adjusted downward to $5.10 per diluted share from a previous estimate of $5.17, reflecting weakening revenue and earnings multiples among comparable companies. The company's Human Nutrition and Health division reported fourth-quarter revenues of $166.1 million, falling short of expectations, while the Animal Nutrition and Health segment also missed targets with sales of $56.4 million. Additionally, several risks, including slower growth, inflationary pressures, and regulatory challenges related to new product launches, contribute to a cautious outlook for Balchem's financial performance.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares